evelopment, regulatory filings and actions. These statements are subject
to risks and uncertainties that could cause actual results and events to
differ materially from those anticipated. Reference should be made to
Onyx's Annual Report on Form 10-K for the year ended December 31, 2007,
filed with the Securities and Exchange Commission under the heading "Risk
Factors" for a more detailed description of such factors, as well as the
Company's subsequent quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements that speak
only as of the date of this release. Onyx undertakes no obligation to
update publicly any forward-looking statements to reflect new information,
events, or circumstances after the date of this release except as required
by law.
(See attached tables.)
ONYX PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------ ------------------
2008 2007 2008 2007
Net revenue from -------- ------- -------- --------
unconsolidated joint
business $39,924 $17,635 $107,860 $28,131
Operating expenses:
Research and development
(1) 10,950 7,901 27,012 19,883
Selling, general and
administrative (1) 19,319 15,245 58,985 44,140
-------- ------- -------- --------
Total operating expenses 30,269 23,146 85
'/>"/>
SOURCE Onyx Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine news :1.
MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents2.
Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review3.
Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference4.
Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference5.
Jazz Pharmaceuticals to Present at Investor Conferences6.
Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference7.
Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call8.
MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates9.
Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes10.
Genesis Pharmaceuticals Files Counter Claims11.
Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results